A Real‐World Cohort Study on the Association of the Use of Sodium‐Glucose Cotransporter‐2 Inhibitor With the Incidence of Chronic Kidney Disease ( Chronic Kidney Disease (CKD) ) in Patients With Type 2 Diabetes Mellitus Without CKD Using the SingHealth Diabetes Registry
Main finding · Incident CKDResult — go to the resultOdds ratio 0.36 95% CI 0.31–0.42Authors' conclusion
SGLT2i use in individuals with T2D and preserved renal function was associated with lower CKD incidence, suggesting its potential preventive role in non-CKD population.
Study context
- Population
- Patients with T2D without CKD (baseline estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m² and urinary albumin-to-creatinine ratio (uACR) < 30 mg/g), SingHealth Diabetes Registry, 2016–2023; matched on age, gender, housing type, BMI, HbA1c, baseline eGFR, RAS inhibitors, metformin and GLP-1 RAanalysed after propensity score matching (PSM)
- Participants
- 4,450 patients
- Exposure
- SGLT2i users vs non-users
- SGLT2i usersn = 2,225
- Non-usersn = 2,225reference
- Outcome
- Incident CKD
Methodological detailspropensity score matching, multi-ethnic Asian population
- Propensity score matching
- Multi-ethnic Asian population
Main finding
As reported in the abstract
Odds ratio
0.36
95% CI 0.31–0.42
P < 0.001
SGLT2i usersvs Non-users
OR 0.36 (95% CI 0.31–0.42); P < 0.001
Observational data: associations, not effects.
Secondary outcomes
Baseline eGFR · median baseline
eGFR and uACR change over time
- Slower rate of GFR decline and lower uACR increase over time in SGLT2i users
Original publication
A Real‐World Cohort Study on the Association of the Use of Sodium‐Glucose Cotransporter‐2 Inhibitor With the Incidence of Chronic Kidney Disease ( CKD ) in Patients With Type 2 Diabetes Mellitus Without CKD Using the SingHealth Diabetes Registry. Diabetes Obes Metab. Published 20 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →